Invivyd (NASDAQ:IVVD – Get Free Report) and iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.
Volatility and Risk
Invivyd has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.
Insider & Institutional Ownership
70.4% of Invivyd shares are held by institutional investors. Comparatively, 97.2% of iTeos Therapeutics shares are held by institutional investors. 17.9% of Invivyd shares are held by insiders. Comparatively, 12.5% of iTeos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Invivyd | $11.56 million | 4.68 | -$198.64 million | ($1.96) | -0.23 |
| iTeos Therapeutics | $35.00 million | 8.10 | -$112.64 million | ($3.15) | -2.46 |
iTeos Therapeutics has higher revenue and earnings than Invivyd. iTeos Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Invivyd and iTeos Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Invivyd | 0 | 0 | 4 | 1 | 3.20 |
| iTeos Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
Invivyd presently has a consensus price target of $7.89, suggesting a potential upside of 1,645.02%. iTeos Therapeutics has a consensus price target of $22.25, suggesting a potential upside of 186.73%. Given Invivyd’s stronger consensus rating and higher possible upside, analysts plainly believe Invivyd is more favorable than iTeos Therapeutics.
Profitability
This table compares Invivyd and iTeos Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Invivyd | N/A | -155.33% | -114.88% |
| iTeos Therapeutics | N/A | -20.11% | -17.50% |
Summary
iTeos Therapeutics beats Invivyd on 7 of the 13 factors compared between the two stocks.
About Invivyd
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
About iTeos Therapeutics
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.
